BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 23, Issue 22
This Article
  • Send to Friends (0)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Checklist of Responsibilities for the Scientific Editor of This Article
Publishing Process of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (7568)
All Articles published online
The chart showing PDF series, WORD series, HTML series, Scan QR Codes (HTML) series, Scan QR Codes (PDF) series, Figures (1-2) series, Tables (1-5) series.
Item 
Count 
PDF565
WORD201
HTML4458
Scan QR Codes (HTML)208
Scan QR Codes (PDF)67
Figures (1-2)70
Tables (1-5)66
 Sum=5635
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse845
Download1363
 Sum=2208
Jun 14, 2017 (publication date) through Mar 27, 2023
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef
For: Koller T, Galambosova M, Filakovska S, Kubincova M, Hlavaty T, Toth J, Krajcovicova A, Payer J. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. World J Gastroenterol 2017; 23(22): 4102-4111 [PMID: 28652663 DOI: 10.3748/wjg.v23.i22.4102]
URL: https://www.wjgnet.com/1007-9327/full/v23/i22/4102.htm
Number Citing Articles
1
Giuseppe Losurdo, Irene Vita Brescia, Chiara Lillo, Martino Mezzapesa, Michele Barone, Mariabeatrice Principi, Enzo Ierardi, Alfredo Di Leo, Maria Rendina. Liver involvement in inflammatory bowel disease: What should the clinician know?. World Journal of Hepatology 2021; 13(11): 1534-1551 doi: 10.4254/wjh.v13.i11.1534
2
Rocco Spagnuolo, Tiziana Montalcini, Daniele De Bonis, Yvelise Ferro, Cristina Cosco, Elisa Mazza, Stefano Romeo, Patrizia Doldo, Arturo Pujia. Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases. Nutrients 2019; 11(2): 303 doi: 10.3390/nu11020303
3
Qiuping Guo, Jianmin Guo, Guiying Chen, Zhong Han, Baiquan Xiao, Ruomin Jin, Chun Liang, Wei Yang. Biomarkers associated with binaprofen‑induced liver injury. Molecular Medicine Reports 2018;  doi: 10.3892/mmr.2018.9549
4
Ya. A. Krasner, Yu. A. Kulygina, E. Yu. Valuyskikh, M. F. Osipenko. Prevalence and characteristics of non-alcoholic steatohepatitis in patients with inflammatory bowel disease in the Novosibirsk region: a cross-sectional, one center study in 245 patients. Almanac of Clinical Medicine 2018; 46(5): 464 doi: 10.18786/2072-0505-2018-46-5-464-473
5
Vlad Alexandru Ionescu, Gina Gheorghe, Valentin Nicolae Varlas, Ana Maria Alexandra Stanescu, Camelia Cristina Diaconu. Hepatobiliary Impairments in Patients with Inflammatory Bowel Diseases: The Current Approach. Gastroenterology Insights 2022; 14(1): 13 doi: 10.3390/gastroent14010002
6
Hélène Céruti, Gilles Kayem, Lucie Guilbaud, Chloé Dussaux, Anne Gervais, Aurélie Beaufrère, Benoit Coffin, Laurent Mandelbrot, Emeline Maisonneuve. Intrahepatic cholestasis of pregnancy associated with azathioprine: A case series. Journal of Gynecology Obstetrics and Human Reproduction 2021; 50(4): 102083 doi: 10.1016/j.jogoh.2021.102083
7
M. Nedim Ince, David E. Elliott. Effective Use of the Laboratory in the Management of Patients with Inflammatory Bowel Diseases. Gastroenterology Clinics of North America 2019; 48(2): 237 doi: 10.1016/j.gtc.2019.02.006
8
Gadour Eyad, Hassan Zeinab. Systematic review and meta-analysis of drug induced liver injury secondary to biologic medications in inflammatory bowel disease. Annals of Clinical Gastroenterology and Hepatology 2021; 5(1): 005 doi: 10.29328/journal.acgh.1001025
9
Paulina Núñez F, Fabiola Castro, Gabriel Mezzano, Rodrigo Quera, Diego Diaz, Lorena Castro. Hepatobiliary manifestations in inflammatory bowel disease: A practical approach. World Journal of Hepatology 2022; 14(2): 319-337 doi: 10.4254/wjh.v14.i2.319
10
Beverley Kok, Erica L. W. Lester, William M. Lee, A. James Hanje, R. Todd Stravitz, Safwat Girgis, Vaishali Patel, Joshua R. Peck, Christopher Esber, Constantine J. Karvellas. Acute Liver Failure from Tumor Necrosis Factor-α Antagonists: Report of Four Cases and Literature Review. Digestive Diseases and Sciences 2018; 63(6): 1654 doi: 10.1007/s10620-018-5023-6
11
Parth Shah, Vinay Sundaram, Einar Björnsson. Biologic and Checkpoint Inhibitor‐Induced Liver Injury: A Systematic Literature Review. Hepatology Communications 2020; 4(2): 172 doi: 10.1002/hep4.1465
12
Fernando Bessone, Einar S. Björnsson. Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors. Medical Clinics of North America 2023;  doi: 10.1016/j.mcna.2022.12.008
13
Shaya Noorian, Yejoo Jeon, Minh T Nguyen, Jenny Sauk, Berkeley N Limketkai. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis. Inflammatory Bowel Diseases 2022; 28(6): 878 doi: 10.1093/ibd/izab199
14
Tomoo Nakagawa, Taku Kobayashi, Kiyohiro Nishikawa, Fumika Yamada, Satoshi Asai, Yukinori Sameshima, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi. Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intestinal Research 2019; 17(4): 504 doi: 10.5217/ir.2019.00030
15
K. BRAZDILOVA, T. KOLLER, Z. KILLINGER, J. PAYER. Prevalence and Risk Factors for Drug-Induced Liver Injury Among Patients With Rheumatic Diseases Treated With Biological Therapy: A Single-Center Experience. Physiological Research 2019; : S157 doi: 10.33549/physiolres.934299
16
Jeroen P.A. Houwen, Antoine C.G. Egberts, Anthonius Boer, Erik M. Maarseveen, Roderick H.J. Houwen, Arief Lalmohamed. Influence of allopurinol on thiopurine associated toxicity: A retrospective population‐based cohort study. British Journal of Clinical Pharmacology 2021; 87(5): 2333 doi: 10.1111/bcp.14625
17
Azathioprine/infliximab. Reactions Weekly 2017; 1664(1): 63 doi: 10.1007/s40278-017-34342-3
18
Zi-Yuan Zou, Bo Shen, Jian-Gao Fan. Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019; 25(11): 1764 doi: 10.1093/ibd/izz043
19
Paulina Núñez F, Rodrigo Quera, Constanza Bay, Fabiola Castro, Gabriel Mezzano. Drug-Induced Liver Injury Used in the Treatment of Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2022; 16(7): 1168 doi: 10.1093/ecco-jcc/jjac013
20
G. V. Volynets, A. I. Khavkin. Inflammatory bowel disease and drug-induced liver damage. Experimental and Clinical Gastroenterology 2021; (10): 138 doi: 10.31146/1682-8658-ecg-194-10-138-146
21
Michele S. Barnhill, Joshua M. Steinberg, Joseph J. Jennings, James H. Lewis. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. Current Gastroenterology Reports 2020; 22(9) doi: 10.1007/s11894-020-00781-3
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345